AR070187A1 - Derivados de dulfonamidas sustituidas - Google Patents
Derivados de dulfonamidas sustituidasInfo
- Publication number
- AR070187A1 AR070187A1 ARP090100139A ARP090100139A AR070187A1 AR 070187 A1 AR070187 A1 AR 070187A1 AR P090100139 A ARP090100139 A AR P090100139A AR P090100139 A ARP090100139 A AR P090100139A AR 070187 A1 AR070187 A1 AR 070187A1
- Authority
- AR
- Argentina
- Prior art keywords
- symbolizes
- aryl
- group
- heteroaryl
- alkyl
- Prior art date
Links
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 10
- 125000003118 aryl group Chemical group 0.000 abstract 10
- 125000001072 heteroaryl group Chemical group 0.000 abstract 10
- 125000006590 (C2-C6) alkenylene group Chemical group 0.000 abstract 6
- 125000003161 (C1-C6) alkylene group Chemical group 0.000 abstract 5
- 125000006591 (C2-C6) alkynylene group Chemical group 0.000 abstract 4
- 125000000623 heterocyclic group Chemical group 0.000 abstract 3
- 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 abstract 2
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 abstract 2
- 229940079593 drug Drugs 0.000 abstract 2
- 239000003814 drug Substances 0.000 abstract 2
- 229910052736 halogen Inorganic materials 0.000 abstract 2
- 150000002367 halogens Chemical class 0.000 abstract 2
- 229940124530 sulfonamide Drugs 0.000 abstract 2
- 150000003456 sulfonamides Chemical class 0.000 abstract 2
- JCXJVPUVTGWSNB-UHFFFAOYSA-N Nitrogen dioxide Chemical compound O=[N]=O JCXJVPUVTGWSNB-UHFFFAOYSA-N 0.000 abstract 1
- 125000002009 alkene group Chemical group 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 150000003254 radicals Chemical class 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Life Sciences & Earth Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Diabetes (AREA)
- Pain & Pain Management (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Cardiology (AREA)
- Rheumatology (AREA)
- Child & Adolescent Psychology (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Heart & Thoracic Surgery (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Dermatology (AREA)
- Pulmonology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Procesos para su preparacion, medicamentos que contengan estos compuestos, y el uso de derivados de sulfonamida sustituida para la preparacion de medicamentos, reguladores de los receptores B1R. Reivindicacion 1: Derivados de la Sulfonamida sustituidos de formula general (1) donde m y n, independientemente el uno del otro, en cada caso, simboliza 0, 1 o 2,; p simboliza 1 o 2; Q simboliza -O-o-CH2-; X simboliza N o CR5; Y simboliza N o CR6; Z simboliza N o CR7; R1 simboliza aril o heteroaril, o simboliza un aril o heteroaril unido a través de un grupo C1-6 alqueno; R2 simboliza H, C1-6-alquilo, aril o heteroaril, o un aril o heteroaril unido a través de un C1-6-grupo de alqueno, grupo C2-6-alkenylene o grupo C2-6-alkinylene; R3 simboliza H, C1-6-alquilo, aril heteroaril, o simboliza un aril o heteroaril unido a través de un grupo C1-6-alquileno, grupo C2-6-alquenileno o grupo C2-6-alquinileno; R4 simboliza H, halogeno, CN, NO2, C1-6-alquilo, aril o heteroaril, o simboliza un aril o heteroaril unido a través de un grupoC1-6-alquileno, grupo C2-6-alquenileno o grupo C2-6-alquinileno; R5, R6 y R7 independientemente el uno del otro, en cada caso, simbolizan H, halogeno, CN, C1-6-alquilo,-NH(C1-6-alquilo), N-(C1-6-alquilo)2, -C1-6-alquileno, -NH(C1-6-alquilo) , -C1-6-alquileno-N (C1-6-alquilo)2, C3-8-cicloalquilo, heterociclilo, aril o heteroaril; o simboliza un heterociclilo, aril o heteroaril unidos por un grupo C1-6-alquileno, grupo C2-6-alquenileno o grupo C2-6-alquinileno; donde los radicales mencionados anteriormente, C1-6-alquilo, C1-6-alquileno, C2-6-alquenileno, C2-6-alquinileno, C3-8-cicloalquilo, heterociclilo, aril y heteroaril pueden ser en cada caso no sustituido o monosustituido o polisustituido con radicales idénticos o diferentes, y de los mencionados radicales C1-6-alquilo, C1-6-alquileno, C2-6-alquenileno, y C2-6-alquinileno pueden en cada caso ser ramificados o no ramificado; en la forma de un enantiomero o diastereomero individual, en la forma de racemato, enantiomeros, diastereomeros, las mezclas de los enantiomeros y/o diastereomeros, así como en cada caso en la forma de sus bases y/o sales fisiologicamente compatibles.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP08000840 | 2008-01-17 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR070187A1 true AR070187A1 (es) | 2010-03-17 |
Family
ID=39539534
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP090100139A AR070187A1 (es) | 2008-01-17 | 2009-01-16 | Derivados de dulfonamidas sustituidas |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US8263598B2 (es) |
| EP (1) | EP2229395A1 (es) |
| JP (1) | JP2011509961A (es) |
| AR (1) | AR070187A1 (es) |
| CA (1) | CA2712265A1 (es) |
| CL (1) | CL2009000085A1 (es) |
| PE (1) | PE20091436A1 (es) |
| WO (1) | WO2009090054A1 (es) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI357902B (en) * | 2005-04-01 | 2012-02-11 | Lg Life Science Ltd | Dipeptidyl peptidase-iv inhibiting compounds, meth |
| TW200944530A (en) * | 2008-04-09 | 2009-11-01 | Gruenenthal Chemie | Substituted sulfonamide derivatives |
| FR2960876B1 (fr) * | 2010-06-03 | 2012-07-27 | Sanofi Aventis | Derives de 3,4-dihydropyrrolo[1,2-a]pyrazine-2,8(1h)-dicarboxamide leur preparation et leur application en therapeutique. |
| CN102464661B (zh) * | 2010-11-16 | 2015-04-01 | 天津药明康德新药开发有限公司 | 一种5,6,7,8-四氢-咪唑并[1,5-a]吡嗪-1-羧酸乙酯的制备方法 |
| WO2012114252A1 (en) | 2011-02-21 | 2012-08-30 | Actelion Pharmaceuticals Ltd | Novel indole and pyrrolopyridine amides |
| CN102229610B (zh) * | 2011-04-22 | 2014-10-29 | 中山大学 | 一种光学纯手性1,2,3,4-四氢吡咯并[1,2-a]吡嗪化合物的合成方法 |
| WO2014111871A1 (en) | 2013-01-17 | 2014-07-24 | Aurigene Discovery Technologies Limited | 4,5-dihydroisoxazole derivatives as nampt inhibitors |
| CN103113324B (zh) * | 2013-02-07 | 2015-08-05 | 浙江工业大学 | 一种n-磺酰基取代的四氢吡咯类化合物的制备方法 |
| EP3377493B1 (en) | 2015-11-20 | 2020-04-08 | Forma Therapeutics, Inc. | Purinones as ubiquitin-specific protease 1 inhibitors |
| CN110709523B (zh) * | 2017-04-12 | 2023-07-11 | 豪夫迈·罗氏有限公司 | 使用经pictet spengler反应获得的加标签的核苷的测序反应方法 |
| CN109956865B (zh) * | 2017-12-22 | 2022-09-13 | 浙江瑞博制药有限公司 | 一种西格列汀中间体的制备方法 |
| CN109956890B (zh) * | 2017-12-23 | 2022-05-10 | 浙江九洲药业股份有限公司 | 一种西格列汀中间体的制备方法 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SE523926C2 (sv) * | 1999-06-15 | 2004-06-01 | Hans Lundqvist | Stentarrangemang |
| AU2004226197B2 (en) * | 2003-03-25 | 2009-12-03 | Laboratoires Fournier S.A. | Benzenesulphonamide derivatives, method for production and use thereof for treatment of pain |
| AU2004240563A1 (en) * | 2003-05-14 | 2004-12-02 | Merck & Co., Inc. | 3-amino-4-phenylbutanoic acid derivatives as dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes |
| WO2007101007A2 (en) | 2006-02-23 | 2007-09-07 | Neurogen Corporation | Aryl sulfonyl heterocycles |
| CA2666406A1 (en) | 2006-10-16 | 2008-04-24 | Gruenenthal Gmbh | Substituted sulfonamide derivatives for use as bradykinin 1 receptor modulators |
-
2009
- 2009-01-15 JP JP2010542577A patent/JP2011509961A/ja active Pending
- 2009-01-15 WO PCT/EP2009/000190 patent/WO2009090054A1/en active Application Filing
- 2009-01-15 CA CA2712265A patent/CA2712265A1/en not_active Abandoned
- 2009-01-15 EP EP09702327A patent/EP2229395A1/en not_active Withdrawn
- 2009-01-16 CL CL2009000085A patent/CL2009000085A1/es unknown
- 2009-01-16 AR ARP090100139A patent/AR070187A1/es not_active Application Discontinuation
- 2009-01-16 PE PE2009000060A patent/PE20091436A1/es not_active Application Discontinuation
- 2009-01-16 US US12/355,337 patent/US8263598B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| US20090186899A1 (en) | 2009-07-23 |
| CA2712265A1 (en) | 2009-07-23 |
| CL2009000085A1 (es) | 2009-03-20 |
| PE20091436A1 (es) | 2009-10-08 |
| WO2009090054A1 (en) | 2009-07-23 |
| US8263598B2 (en) | 2012-09-11 |
| EP2229395A1 (en) | 2010-09-22 |
| JP2011509961A (ja) | 2011-03-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR070187A1 (es) | Derivados de dulfonamidas sustituidas | |
| DOP2019000083A (es) | COMPUESTOS DE BENZO[b]TIOFENO COMO AGONISTAS DE STING | |
| CR9459A (es) | Derivados benzodioxano y benzodioxolano y usos de los mismos | |
| UY30835A1 (es) | 8-alquinilxantinas y derivados | |
| AR079510A1 (es) | Derivados de quinolinamida moduladores alostericos positivos de receptores muscarinicos m1, composiciones farmaceuticas que los contienen y uso de los mismos en el tratamiento del alzheimer, esquizofrenia y otras patologias del sistema nervioso central. | |
| AR081628A1 (es) | 5-fluoro-1h-pirazolopiridinas sustituidas y su uso | |
| AR075892A1 (es) | Derivados de benzotiadiazepinas, su procedimiento de preparacion y composiciones farmaceuticas que los contienen | |
| AR062677A1 (es) | Derivados de biaril-sulfonamida, procesos de produccion y composiciones farmaceuticas que los comprenden | |
| ECSP18024565A (es) | Benzamidas sustituidas con isoxazolinas y análalogos como insecticidas | |
| AR096979A1 (es) | Derivados de pirrol, su procedimiento de preparación y las composiciones farmacéuticas que los contienen | |
| UY31126A1 (es) | Derivados de quinoxalina como inhibidores de la actividad de cinasa de tirosina de las cinasas janus | |
| AR091790A1 (es) | Derivados de isoquinolin-1-ona y sus usos | |
| AR072016A1 (es) | Derivados de isoxazol que funcionan como potenciadores de los receptores de glutamato | |
| UY31712A1 (es) | Nuevos derivados de diosmetina, su procedimiento de preparacion y las composiciones farmacéuticas que los contienen | |
| UY33484A (es) | Derivados de dioxido de 1,3-propano sustituidos por espirociclos, procedimientos de obtencion y uso medico | |
| UY31651A1 (es) | Nuevos derivados de fluoroglicósidos aromáticos, medicamentos que comprenden estos compuestos y uso de los mismos. | |
| AR065587A1 (es) | Aminoamidas como antagonistas de orexina | |
| AR056121A1 (es) | 4-oxi-n- [1.3.4 -tiadiazol-2-il-bencenosulfonamidas, procesos para su preparacion y su uso como productos farmaceuticos | |
| UY29749A1 (es) | Antagonistas de cgrp seleccionados, procedimientos para su preparación, así como su uso como medicamentos | |
| UY31287A1 (es) | Antagonistas del receptore de bradiquinina b1. sus procesos de preparación y aplicaciones. | |
| CR9499A (es) | Nuevos derivados de fenilpiridinilpiperazina, su procedimiento de preparacion y las composiciones farmaceuticas que los contienen | |
| UY35685A (es) | Compuestos de dióxido de amino tiazina bicíclicos puenteados como inhibidores de beta-secretasa y sus métodos de uso | |
| BR112013024957A2 (pt) | derviado de furanona ou um sal farmaceuticamente aceitável do mesmo | |
| BR112013005823B8 (pt) | Compostos heterocíclicos para o tratamento ou prevenção de distúrbios causados pela neurotransmissão reduzida de serotonina, norefnefrina ou dopamina | |
| CU20100073A7 (es) | Nuevos derivados no peptídicos como antagonistas b1 de la bradiquinina |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal |